Novel Technologies

Novel Technologies focuses on addressing key research gaps to enable interception and improve remission rates in IBD. This includes testing predictions of disease onset and progression, developing novel technologies tailored to specific phenotypes, and facilitating collaborative translation of science into diagnostics, devices, and therapeutics.


Proposed priority actions include real-time measurement of biological changes preceding disease onset, more effective quantification of fibrosis, exploration of technologies for local treatment of fistulas and the development of drug delivery platforms for precise, location-restricted therapies. Additionally, there's a strong emphasis on fostering collaboration between various stakeholders to accelerate progress in IBD research and treatment.



Refer to our current research funding opportunities that incorporates the priorities summarized above.